Harry Warnke

TL;DR: Intravenous epoetin beta treatment of 5 × 500 U/kg BW in combination with 300 mg Fe2+ orally per day administered over 14 days preoperatively is an adequate therapy for increasing mean hemoglobin levels by approximately 1.50 g/dL and reducing the allogeneic blood requirement in patients undergoing elective open-heart surgery and in whom ABD is contraindicated.

TL;DR: It is stated that rhEPO treatment, where strictly indicated, is a safe form of therapy and the risk of side effects in certain predisposed patients must also be weighed against the desired clinical benefits.

TL;DR: The treatment of recombinant human erythropoietin with heparin seems to be a safe way for increasing mean hematocrit by approximately 0.06 within the normal range and reducing the homologous blood requirement in patients undergoing elective cardiac surgery.

TL;DR: A new technique for the transvenous implantation of a specially designed atrial sensing electrode in combination with a ventricular stimulating electrode and an atrial-controlled pacemaker enables synchronization of atrial with ventricular activity.

TL;DR: Preoperative epoetin beta therapy is a safe way of providing increased extractable O2 and decreasing the risk of lactic acidosis after surgery and has a more favorable effect on the O2 binding curve than the transfusion of erythrocyte concentrate and enhances the effect of epoetic therapy on the postoperative oxygen status.